Fast-acting human insulin - Adocia

Drug Profile

Fast-acting human insulin - Adocia

Alternative Names: BC-222 human insulin; BioChaperone® Human Insulin; BioChaperone® rhInsulin; HinsBet; Hinsbet-U500; HinsBet® U100

Latest Information Update: 09 Nov 2016

Price : $50

At a glance

  • Originator Adocia
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Diabetes mellitus

Highest Development Phases

  • Phase II Type 1 diabetes mellitus
  • Preclinical Type 2 diabetes mellitus

Most Recent Events

  • 27 Oct 2016 Safety and efficacy data from a phase Ib trial in Type-1 diabetes released by Adocia
  • 01 Aug 2016 Adocia completes a phase I/II trial for Type-1 diabetes mellitus in Germany (NCT02739906)
  • 14 Apr 2016 Adocia plans a phase I/II trial for Type-1 diabetes mellitus in Germany (SC) (NCT02739906)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top